GlobeNewswire by notified

ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery

Share

SOLANA BEACH, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has entered into a multi-year license agreement with UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical leader, to partner on drug delivery platforms for UCB’s gene therapy portfolio.

“We are extremely excited to partner with UCB, a global biopharmaceutical leader, with a focus on innovating through the adoption of next generation science and new technologies,” stated Jeremy Stigall, Executive Vice President and General Manager of Biologics and Drug Delivery at ClearPoint Neuro. “Over the past year, we have invested heavily in expanding our Biologics and Drug Delivery team, as well as our product and services portfolio to attract partners of UCB’s caliber. UCB sought comprehensive tools to empower a seamless transition from benchtop testing to commercial success, and that’s precisely what our team can deliver today.”

Under the terms of the license agreement, UCB will utilize ClearPoint Neuro’s proprietary technology and services in connection with the development and commercialization of UCB’s gene therapy products. ClearPoint Neuro will receive success-based milestone payments. Further financial details of the agreement were not disclosed.

Dhaval Patel, Executive Vice President and UCB’s Chief Scientific Officer, said, “We look forward to the ClearPoint Neuro collaboration as we work on advancing UCB’s research and development pipeline in gene therapy. We believe that ClearPoint Neuro are a strong strategic fit for UCB as they are a company dedicated to innovation in the neurology space with a unique portfolio of navigation and drug delivery tools.”

About ClearPoint Neuro

ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 65 active sites in North America, Europe, and South America. ClearPoint Neuro is partnered with more than 50 pharmaceutical/biotech companies, academic centers, and contract research organizations providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 6,000 procedures have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.

Forward-Looking Statements

Statements in this press release and in the teleconference referenced above concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, the size of total addressable markets or the market opportunity for the Company’s products and services, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of the COVID-19 pandemic, global instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenue from sales of the Company’s ClearPoint Neuro Navigation System and other new products offered by the Company; the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System and other new products offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of our products and services in their delivery of therapies; and risks inherent in the research and development of new products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, which has been filed with the Securities and Exchange Commission, and the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2023, which the Company filed with the Securities and Exchange Commission on May 15, 2023.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Nokia Corporation: Repurchase of own shares on 26.09.202326.9.2023 20:00:00 CEST | Press release

Nokia Corporation Stock Exchange Release 26 September 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 26.09.2023 Espoo, Finland – On 26 September 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL311,0543.56CEUX55,9623.57AQEU8,7573.55TQEX16,2273.57Total392,0003.56 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 Januar

Sunstone IV hf. announces Consolidated Condensed Interim Financial Statements for the six months ended June 30, 202326.9.2023 19:56:38 CEST | Press release

Sunstone IV hf. Storhofdi 22-30, 110 Reykjavik, Iceland Sunstone IV hf. announces Consolidated Condensed Interim Financial Statements for the six months ended June 30, 2023 Consolidated condensed interim financial statements, for the six months ended June 30, 2023 of Sunstone IV hf. were approved at a Board of Directors meeting on 21 September 2023. The financial statements can be found on the Company’s website: https://www.mila.is/um-milu/fjarmal/sunstone-iv/ For more information please contact: Inga Helga Halldórudóttir Compliance officer Sunstone IV hf. ingah@mila.is

Nokia to bring semiconductor expertise to CHIPS and Science Act funded innovation hub26.9.2023 18:20:01 CEST | Press release

Press Release Nokia to bring semiconductor expertise to CHIPS and Science Act funded innovation hub Nokia will join a new innovation hub that seeks to expand U.S. global leadership in microelectronics technical development.The program will help reduce U.S. reliance on foreign microelectronics and safeguard supply chain risks, while ensuring access to cutting edge semiconductors for the Department of Defense. 26 September 2023 Murray Hill, New Jersey – Nokia today announced that it is part of the Northeast Microelectronics Coalition (NEMC) Hub, a regional innovation hub led by the Massachusetts Technology Collaborative (MassTech). The NEMC Hub was recently awarded funding to advance the microelectronics needs of the U.S. Department of Defense (DoD) from the "Creating Helpful Incentives to Produce Semiconductors (CHIPS) and Science Act." The funding award will establish a total of eight Microelectronics Commons regional innovation hubs and Core Facilities distributed across the United St

ABC arbitrage : Continuation of liquidity contract of ABC ARBITRAGE26.9.2023 18:00:00 CEST | Press release

Continuation of liquidity contract of ABC ARBITRAGE ABC ARBITRAGE informs that it will continue the liquidity contract with Kepler Cheuvreux, adding the following additional resources: 80,000 in cash (transfer executed on 21 September 2023). As a reminder : • the following resources appeared on the last half year statement on 30 June 2023 on the liquidity account: - 51,410 shares - € 111,829.43 - Number of executions on buy side on semester: 783 - Number of executions on sell side on semester: 1,120 - Traded volume on buy side on semester: 125,924 shares for € 781,516.85 - Traded volume on sell side on semester: 115,527 shares for € 719,846.14 • the following resources appeared on the liquidity account when the activity started: - 28,440 shares - € 49,007.93 The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice. Contacts : abc-arbitrage.com

ROBIT PLC: REPURCHASE OF OWN SHARES 26 SEPTEMBER 202326.9.2023 17:45:00 CEST | Press release

ROBIT PLC STOCK EXCHANGE RELEASE 26 SEPTEMBER 2023 AT 18.45 EEST ROBIT PLC: REPURCHASE OF OWN SHARES26 SEPTEMBER 2023 Robit PlcNasdaq Helsinki LtdDate26.9.2023Exchange transactionBUYShare trading codeROBITAmount, shares1765Average price / share, EUR1,453666Total cost, EUR2565,72 Robit Plc now holds a total of 17 479 shares including the shares repurchased on 26 September 2023. Detailed information concerning the repurchase is attached to this stock exchange release. On behalf of Robit Plc OP Corporate Bank Mikael Ahovuo Further information: Robit Plc Arto Halonen, Group CEO +358 40 028 0717 arto.halonen@robitgroup.com Distribution: Nasdaq Helsinki Ltd Key media www.robitgroup.com Robit is the specialist focused on high quality drilling consumables for the mining and construction markets globally to help you drill even Further. Faster. Robit strives to be the world’s number one drilling consumables company. Through our proven, high-quality Top Hammer, Down the Hole and Geotechnical prod